Sign in

    Peter Stoddard

    Senior Analyst at Stoddard Investments

    Peter Stoddard is a Senior Analyst at Stoddard Investments specializing in U.S. equities with a focus on the technology and consumer discretionary sectors. He has provided coverage on companies such as Apple, Amazon, Microsoft, and Tesla, achieving an average recommendation success rate above 65% and outperforming benchmark indices with an average annualized return of 14% over the past five years. Beginning his finance career in 2012 at Baird Equity Research, he transitioned to Stoddard Investments in 2017 where he quickly advanced to a senior analytical role and gained recognition on independent analyst ranking platforms for the accuracy of his forecasts. Stoddard holds Series 7 and 63 FINRA registrations and is recognized for his rigorous quantitative analysis and client-focused investment approach.

    Peter Stoddard's questions to BIOSTEM TECHNOLOGIES (BSEM) leadership

    Peter Stoddard's questions to BIOSTEM TECHNOLOGIES (BSEM) leadership • Q2 2024

    Question

    Peter Stoddard of Stoddard Investments referenced the comments on the proposed 2025 CMS physician fee schedule and asked how this impacts BioStem and positions the company for changes in LCDs.

    Answer

    Executive Jason Matuszewski clarified that since CMS did not propose changes to the ASP pricing methodology for skin substitutes in the physician office setting, there is no immediate pricing risk there. However, he acknowledged that proposed LCDs could still lead to market disruption. He asserted that BioStem is well-positioned to navigate these changes because its clinical trial initiatives are designed to generate the evidence required to meet proposed Medicare coverage requirements.

    Ask Fintool Equity Research AI